Baseline characteristics
| Group | Statin+BPRx | BPRx | Placebo | Statin |
| Patients, n | 7227 | 6539 | 6452 | 6802 |
| Age, years | 63.2 (7.7) | 63.7 (7.6) | 63.7 (7.6) | 63.6 (7.5) |
| Men, % | 64.2 | 65.4 | 66.9 | 64.5 |
| BMI, kg/m2 | 27.7 (4.8) | 27.7 (4.7) | 27.6 (4.6) | 27.7 (4.7) |
| Smoking, % | 30.9 | 30.3 | 30.5 | 30.1 |
| Previous CVD, % | 9.2 | 7.3 | 7.0 | 8.1 |
| Previous MI, % | 1.3 | 1.4 | 1.3 | 1.4 |
| Type 2 diabetes, % | 14.3 | 14.4 | 14.0 | 14.2 |
| Hypertension, % | 65.9 | 62.1 | 61.9 | 63.5 |
| SBP, mm Hg | 148.3 (15.3) | 148.4 (16.1) | 147.8 (16.0) | 148.2 (15.9) |
| DBP, mm Hg | 87.6 (9.2) | 87.2 (9.6) | 87.0 (9.5) | 87.2 (9.5) |
| Hyperlipidaemia, % | 30.3 | 21.6 | 20.9 | 24.7 |
| LDL cholesterol, mM | 3.57 (0.85) | 3.46 (0.84) | 3.44 (0.84) | 3.51 (0.83) |
| HDL cholesterol, mM | 1.22 (0.36) | 1.22 (0.35) | 1.22 (0.36) | 1.22 (0.35) |
BMI, body mass index; BPRx, blood pressure-lowering treatment; CVD, cardiovascular disease; DBP, diastolic blood pressure, HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; SBP, systolic blood pressure.